Chimeric antigen receptor (CAR) T-cell therapy for people with relapsed or refractory diffuse large B-cell lymphoma
Goldkuhle M., Ernst M., Estcourt LJ., Borchmann P., Monsef I., Skoetz N.
© 2019 The Cochrane Collaboration. This is a protocol for a Cochrane Review (Intervention). The objectives are as follows: To assess the benefits, harms and costs of chimeric antigen receptor (CAR) T-cell therapy for people with relapsed or refractory diffuse large B-cell lymphomas (DLBCLs) in accordance with the available body of evidence.